Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

The shift shows up clearly in market valuations. At the end of March 2024, Novo Nordisk was worth over $500 billion and Lilly ...

Research reveals Eli Lilly's GLP-1 drug, tirzepatide, temporarily suppresses food cravings in a patient's brain reward center. While initial effects were promising, the impact faded over time. Results ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...